EGFR and non-small cell lung carcinoma: Currently under evaluation in EGFR exon 20 insertion mutant NSCLC are small molecule kinase inhibitors (poziotinib, mobocertinib, CLN-081, BDTX-189, DZD9008) as well combination treatments of standard EGFR kinase inhibitors approved for classical EGFR mutant NSCLC (afatinib or osimertinib) with anti-EGFR mAbs (cetuximab, necitumumab and JMT101).